Literature DB >> 30215204

Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.

Haijun Han1,2, Zhongli Yang1,3, Sulie L Chang4,5, Ming D Li6,7,8.   

Abstract

Nicotine, one of the key active ingredients in tobacco smoke, exerts its effects via binding to nicotinic acetylcholine receptors (nAChRs). Although both negative and positive pharmacological effects of nicotine have been shown in numerous animals and human studies, its interaction with human immunodeficiency virus-1 (HIV-1) have not been fully elucidated. Even though combined anti-retroviral therapy (cART) limits the progression of HIV-1 to acquired immune deficiency syndrome (AIDS), HIV-associated neurocognitive disorders (HAND) remain prevalent. There is thus a compelling need to enhance our understanding of HAND-related neurologic dysfunction. Some biochemical pathways and physiological dysfunctions have been found to be shared by HAND and Alzheimer's (AD) or Parkinson's (PD) diseases, and nicotine may exert the same neuroprotection in HAND that has been observed in both AD and PD. In the past dozen years, various potential therapeutic effects of nicotine such as neuroprotection have been revealed in both in vivo and in vitro studies, including using HIV-1 transgenic (HIV-1Tg) rat model, which mimics HIV-infected patients receiving cART. In the current review, we describe recent progress in the prevalence of HIV/AIDS with and without cigarette smoking, some animal models for studying neural dysfunction associated with HIV-1 infection, elucidating the modulatory effects of cigarette smoking/nicotine on HIV/AIDS, the anti-inflammatory effects of nicotine, and the neuroprotective effects observed in HIV-1Tg rat model. Taken together, these findings suggest the following: although tobacco smoking does cause deleterious effects in both health and disease conditions such as HIV infection, nicotine, the significant component of tobacco smoke, has been shown to possess some neuroprotective effects in HIV patients, possible via its anti-inflammatory activities. It is therefore necessary to study nicotine's dual effects on neuroHIV/neuroAIDS in hope of better defining the potential medical uses of nicotine or its analogues, and to make them available in a purer and less dangerous form.

Entities:  

Keywords:  Anti-inflammation; HIV-associated neurocognitive disorders; HIV/AIDS; Neuroprotection; Nicotine

Mesh:

Substances:

Year:  2018        PMID: 30215204      PMCID: PMC6375072          DOI: 10.1007/s11481-018-9806-5

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  147 in total

Review 1.  Inflammation and therapeutic vaccination in CNS diseases.

Authors:  Howard L Weiner; Dennis J Selkoe
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 2.  Modeling HIV infection and therapies in humanized mice.

Authors:  Marc Nischang; Gustavo Gers-Huber; Annette Audigé; Ramesh Akkina; Robert F Speck
Journal:  Swiss Med Wkly       Date:  2012-07-09       Impact factor: 2.193

3.  Applying Public Health Principles to the HIV Epidemic--How Are We Doing?

Authors:  Thomas R Frieden; Kathryn E Foti; Jonathan Mermin
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

Review 4.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

5.  Toward an AIDS-free generation.

Authors:  Anthony S Fauci; Gregory K Folkers
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

Review 6.  Overcoming current limitations in humanized mouse research.

Authors:  Michael A Brehm; Leonard D Shultz; Jeremy Luban; Dale L Greiner
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

Review 7.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

Review 8.  Nicotine and inflammatory neurological disorders.

Authors:  Wen-Hua Piao; Denise Campagnolo; Carlos Dayao; Ronald J Lukas; Jie Wu; Fu-Dong Shi
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

Review 9.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

10.  The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART.

Authors:  Jinsong Peng; Michael Vigorito; Xiangqian Liu; Dunjing Zhou; Xiongwen Wu; Sulie L Chang
Journal:  J Neuroimmunol       Date:  2009-11-13       Impact factor: 3.478

View more
  4 in total

1.  Editors' Commentary for Special Issue: The 2017 CALDAR Summer Institute and International Conference Promoting Global Health-Precision Research in Substance Abuse, HIV, and Care.

Authors:  Linda Chang; Ming D Li; Yih-Ing Hser
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-31       Impact factor: 4.147

2.  Contributions of chronic tobacco smoking to HIV-associated brain atrophy and cognitive deficits.

Authors:  Hua-Jun Liang; Thomas Ernst; Eric Cunningham; Linda Chang
Journal:  AIDS       Date:  2022-03-15       Impact factor: 4.177

Review 3.  Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.

Authors:  Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-13       Impact factor: 4.147

4.  Nicotine self-administration with menthol and audiovisual cue facilitates differential packaging of CYP2A6 and cytokines/chemokines in rat plasma extracellular vesicles.

Authors:  Asit Kumar; Namita Sinha; Sanjana Haque; Sunitha Kodidela; Tengfei Wang; Angel G Martinez; Hao Chen; Santosh Kumar
Journal:  Sci Rep       Date:  2021-08-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.